<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2"><gtr:id>9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2</gtr:id><gtr:firstName>Gurdyal Singh</gtr:firstName><gtr:surname>Besra</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C729E8DE-F8AA-4EAD-9C0D-78FA2F948D3F"><gtr:id>C729E8DE-F8AA-4EAD-9C0D-78FA2F948D3F</gtr:id><gtr:firstName>David Ernest</gtr:firstName><gtr:surname>Minnikin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC56C359-8F37-4BAF-B2E4-8C55DC097D1A"><gtr:id>DC56C359-8F37-4BAF-B2E4-8C55DC097D1A</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Lammas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500590"><gtr:id>DBF8F736-0934-48EA-86BE-1FC8927EFE0B</gtr:id><gtr:title>The Mycobacterial Cell Wall: Structure, Function and Biosynthesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500590</gtr:grantReference><gtr:abstractText>Tuberculosis (TB) is a life?threatening condition that can last for several years during which patients are debilitated and may disseminate the bacterium that causes the disease, Mycobacterium tuberculosis (Mtb). At least 30 million individuals worldwide will have died from TB in the last decade of the 20th century. In the UK the steady decline in TB cases over the whole of the last century halted in the mid 1980s and there has been alarming signs of increased numbers of cases in certain communities. The situation is compounded by the AIDS epidemic and by the emergence of Mtb strains that are resistant to virtually all the drugs that would normally be used to treat TB. It can be argued that, globally, Mtb is the single most important infectious agent affecting mankind. All bacteria have cells that, like plants, are enclosed in a cell wall. This protects the organism from its immediate environment and, fortuitously, presents an important target for drugs, like penicillin, that can be used to treat bacterial infections. However, Mtb has a distinctive cell wall that differs in composition from that of other bacteria; in particular it contains an exceptional amount of unique lipids (fats) and sugars. Although there are drugs that affect the unique Mtb cell wall, the current treatment for tuberculosis lasts 6 months and is potentially toxic to patients who often cease treatment early. Moreover, the efficacy of treatment is threatened by the emergence of drug-resistant strains of Mtb. There is therefore a great need for new and better drugs to treat TB. 

Communication to the general public will be channelled through the University Press Office at Birmingham (http://www.newscentre.bham.ac.uk/office.htm) which has established contacts in the local and national media. The MRC Co-operative Group members will also highlight there research through personal University based Web pages, which has open access. This highlights the clinical and research elements of the MRC Co-operative Group.</gtr:abstractText><gtr:technicalSummary>The research grant is aimed at coordinating a continued integrated investigation into the basic biochemistry and physiology of the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex and associated free lipids in the cell envelope of Mycobacterium tuberculosis. Mycolic acids are essential envelope components and substantial current progress will be vigorously continued into understanding the enzymology of mycolate synthesis, particularly for condensing and transferase enzymes. Mycolates are supported on an arabinogalactan, linked to the basal cell wall peptidoglycan; the glycosyltransferases involved in the assembly of this complex arabinogalactan matrix will continue to be characterised, as will the related enzymes leading to the prime envelope lipoarabinomannan immunogen. A range of characteristic waxes and antigenic acylated trehalose glycolipids are expressed on the cell surface and the detailed immunology and pathogenic role of these will be unravelled, revealing innovative directions for the treatment or prevention of tuberculosis. All of the above prime investigations will exploit the full power of a multi-disciplinary approach using biochemistry, chemistry, immunology and molecular biology.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>431949</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>New TB drug targets and vaccines</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>591C59AC-CA9F-4726-968B-C3A9C3ED2460</gtr:id><gtr:impact>An interview with the BBC Inside Out show.

None</gtr:impact><gtr:outcomeId>4652622D6AE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BCG Vaccine and problems?</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4656E492-AE6A-4AA9-B7D8-3D6478037E00</gtr:id><gtr:impact>BBC Inside Out

None</gtr:impact><gtr:outcomeId>0EBFE84C19D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB drugs and vaccines?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5DAF222A-8DDB-4DAF-AF0F-5189F75F0EFA</gtr:id><gtr:impact>Interview with the BBC and Inside Out Show for the West Midlands.

None</gtr:impact><gtr:outcomeId>DF6B35BD584</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB drugs?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ED1B6E38-9EE8-4BB2-8F4B-B89EB47040C8</gtr:id><gtr:impact>Interview and presentation for the BBC Inside Out

None</gtr:impact><gtr:outcomeId>D491B41401A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB Drugs</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EC4872FB-FB62-4004-BD97-F2ECB94A494A</gtr:id><gtr:impact>Interview for BBC Inside Out.

None</gtr:impact><gtr:outcomeId>57DE7FE480A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>396721</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0901690</gtr:fundingRef><gtr:id>B22AE6EC-9E60-42C5-96D8-C0B637BBF126</gtr:id><gtr:outcomeId>m1KKnri6gVB</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>301358</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001023</gtr:fundingRef><gtr:id>94271C69-C3F3-42F0-8F16-389793210D4A</gtr:id><gtr:outcomeId>BA8RtVaMs4j</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1778106</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K012118/1</gtr:fundingRef><gtr:id>8C7F1594-5502-4C61-BD12-69630ADDBEE7</gtr:id><gtr:outcomeId>HjBnDj6fNHB</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1226535</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (An integrated multi-disciplinary approach to unravel complex and essential cell wall biosynthetic pathways involved in arabinogalactan and lipoarabinomannan assembly in Mycobacterium tuberculosis)</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>9F56B796-7BAB-4082-8EE3-B8EA5838AC23</gtr:id><gtr:outcomeId>A88210C69AC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>081D57E3-3114-45BC-A7E7-0CEBB6EC345C</gtr:id><gtr:title>Inhibition of Escherichia coli glycosyltransferase MurG and Mycobacterium tuberculosis Gal transferase by uridine-linked transition state mimics.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/676407c0259a1bdcb89937ad70f93e17"><gtr:id>676407c0259a1bdcb89937ad70f93e17</gtr:id><gtr:otherNames>Trunkfield AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>DkA3wwNKnHJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B64B489-FCB8-4DA6-AEB7-1054B46E1A4B</gtr:id><gtr:title>Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3125c235119e244a21e2a4774907109e"><gtr:id>3125c235119e244a21e2a4774907109e</gtr:id><gtr:otherNames>Al-Balas Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>86BFCBBBF10</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7064D0B5-A045-4E85-8B3B-BE6EC2D5451C</gtr:id><gtr:title>Biochemical characterization of the Mycobacterium tuberculosis phosphoribosyl-1-pyrophosphate synthetase.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/938585ac20ff7a91cc730466157b3634"><gtr:id>938585ac20ff7a91cc730466157b3634</gtr:id><gtr:otherNames>Alderwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>ZyoZnbxVniZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC2AC778-16AD-4699-895C-773A528E6B17</gtr:id><gtr:title>Identification of a terminal rhamnopyranosyltransferase (RptA) involved in Corynebacterium glutamicum cell wall biosynthesis.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cc553143c062c43864af4ca99cc7410"><gtr:id>2cc553143c062c43864af4ca99cc7410</gtr:id><gtr:otherNames>Birch HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>291B115DF04</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C04F9CC-1832-4A3B-B43A-05404A21C744</gtr:id><gtr:title>Mycobacterium tuberculosis acyl carrier protein synthase adopts two different pH-dependent structural conformations.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a6c6b6a8e6ed98aee7f3350ada3177e"><gtr:id>0a6c6b6a8e6ed98aee7f3350ada3177e</gtr:id><gtr:otherNames>Gokulan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>FZ5LEjvhiat</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC7AE6CD-7BC9-416E-AD56-15C0D5CB9490</gtr:id><gtr:title>Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction.</gtr:title><gtr:parentPublicationTitle>FEMS microbiology reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1764466a9db2af8c2be90c94ee57fb4e"><gtr:id>1764466a9db2af8c2be90c94ee57fb4e</gtr:id><gtr:otherNames>Mishra AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-6445</gtr:issn><gtr:outcomeId>Fp5J2x8XdAU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26E75D0A-6BAD-4C5A-9193-1ACAA4924009</gtr:id><gtr:title>Synthesis of symmetrical C- and pseudo-symmetrical O-linked disaccharide analogs for arabinosyltransferase inhibitory activity in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/129e6a7d89b1eeef536815288f3004e2"><gtr:id>129e6a7d89b1eeef536815288f3004e2</gtr:id><gtr:otherNames>Pathak AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>F45BD219737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66FE5112-A46B-4740-879D-28640564C47E</gtr:id><gtr:title>Acceptor substrate discrimination in phosphatidyl-myo-inositol mannoside synthesis: structural and mutational analysis of mannosyltransferase Corynebacterium glutamicum PimB'.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26ce5b95a0680e7fff939abf059c13ed"><gtr:id>26ce5b95a0680e7fff939abf059c13ed</gtr:id><gtr:otherNames>Batt SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>gY26cRrafvt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>017FC4DB-161D-4CEF-A6D1-02A2CFC3837E</gtr:id><gtr:title>Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eda599b4896f2b981d5bdb5f92f960f"><gtr:id>9eda599b4896f2b981d5bdb5f92f960f</gtr:id><gtr:otherNames>Im JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>F66372730EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6989B389-94EE-4002-9C54-7B9EAD72319D</gtr:id><gtr:title>Platensimycin activity against mycobacterial beta-ketoacyl-ACP synthases.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/962767f96f457e07606b64e91d28b5fd"><gtr:id>962767f96f457e07606b64e91d28b5fd</gtr:id><gtr:otherNames>Brown AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5C84AA20717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8856926E-C0EE-4F45-94E4-3B482E1D9D6E</gtr:id><gtr:title>Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars.</gtr:title><gtr:parentPublicationTitle>Protein &amp; cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41e02cc55965b9298adffc5897b6e1b"><gtr:id>a41e02cc55965b9298adffc5897b6e1b</gtr:id><gtr:otherNames>Westwood IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1674-800X</gtr:issn><gtr:outcomeId>CaiixKBXtLq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AEA1810-CE00-4CB4-8930-4A062588ECE5</gtr:id><gtr:title>Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II dehydratase enzyme Rv0636.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/749291bc8fb7017a50d46025281050b0"><gtr:id>749291bc8fb7017a50d46025281050b0</gtr:id><gtr:otherNames>Bhowruth V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn><gtr:outcomeId>AE8E7B5623B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA2EE675-6A5E-4DD6-BED3-3955E175F929</gtr:id><gtr:title>Synthesis of deoxygenated alpha(1--&amp;gt;5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/129e6a7d89b1eeef536815288f3004e2"><gtr:id>129e6a7d89b1eeef536815288f3004e2</gtr:id><gtr:otherNames>Pathak AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>1D9E5306C84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BA7C7CE-FCB7-45A8-B24A-7C7C01F0FEB0</gtr:id><gtr:title>Modular approach to triazole-linked 1,6-a-D-oligomannosides to the discovery of inhibitors of Mycobacterium tuberculosis cell wall synthetase.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b7ca0b14131710bba6bac64491cfc31"><gtr:id>2b7ca0b14131710bba6bac64491cfc31</gtr:id><gtr:otherNames>Lo Conte M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>ric3zYhzxhX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1609F2C0-4179-445E-8851-0616640935D8</gtr:id><gtr:title>Loss of a mycobacterial gene encoding a reductase leads to an altered cell wall containing beta-oxo-mycolic acid analogs and accumulation of ketones.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fab35eba433db30e03147923f9c6b63d"><gtr:id>fab35eba433db30e03147923f9c6b63d</gtr:id><gtr:otherNames>Bhatt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>7BFF8FBCBFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA016188-8D61-408A-AF33-5C3829B63EF3</gtr:id><gtr:title>The Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5f29095b885dea11ffc2e214b0781c7"><gtr:id>b5f29095b885dea11ffc2e214b0781c7</gtr:id><gtr:otherNames>Veyron-Churlet R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CFF18C42BEC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4495E54C-19C2-48C5-A8AD-E21227C1928E</gtr:id><gtr:title>Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286e637dccc3e05c93cc3ebe3583bb1c"><gtr:id>286e637dccc3e05c93cc3ebe3583bb1c</gtr:id><gtr:otherNames>Usha V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn><gtr:outcomeId>BL4mAC3Uvub</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1727E212-152B-443F-86B5-B987CF0EE395</gtr:id><gtr:title>Mannan chain length controls lipoglycans signaling via and binding to TLR2.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f1c9aa4c0f3f386f852ceb795b757e8"><gtr:id>9f1c9aa4c0f3f386f852ceb795b757e8</gtr:id><gtr:otherNames>Nigou J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>6666C97A3F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFCE33C6-6B72-417C-AACD-2D37E35EB325</gtr:id><gtr:title>Inactivation of Corynebacterium glutamicum NCgl0452 and the role of MgtA in the biosynthesis of a novel mannosylated glycolipid involved in lipomannan biosynthesis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a10ca0f4eb0dcb93009bf9ad8cb79c29"><gtr:id>a10ca0f4eb0dcb93009bf9ad8cb79c29</gtr:id><gtr:otherNames>Tatituri RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>1D1BAE58BDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02A2DDFA-7133-4924-8688-D98C5C75C047</gtr:id><gtr:title>Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an alpha-glucan pathway.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b2c58e57e9ab1ad2c24e9a9f0d3183"><gtr:id>a1b2c58e57e9ab1ad2c24e9a9f0d3183</gtr:id><gtr:otherNames>Kalscheuer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>o6aijmVbm5W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5DFAFDD-1A12-4A46-A276-FFFC785B1131</gtr:id><gtr:title>Disaccharide analogs as probes for glycosyltransferases in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/129e6a7d89b1eeef536815288f3004e2"><gtr:id>129e6a7d89b1eeef536815288f3004e2</gtr:id><gtr:otherNames>Pathak AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>3A704494CE6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5788D8ED-380A-4716-9BF7-FAAF11DC23AD</gtr:id><gtr:title>A truncated lipoglycan from mycobacteria with altered immunological properties.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cc553143c062c43864af4ca99cc7410"><gtr:id>2cc553143c062c43864af4ca99cc7410</gtr:id><gtr:otherNames>Birch HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>EAgAbzYarNq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBA91A6A-F86F-44A9-B55F-C5E9F2EEBA5F</gtr:id><gtr:title>Glycomimetic inhibitors of mycobacterial glycosyltransferases: targeting the TB cell wall.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93d902eed75d07a732682813163af0a9"><gtr:id>93d902eed75d07a732682813163af0a9</gtr:id><gtr:otherNames>Lucas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>75BFDD31C35</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B8A7E99-52F4-47B2-832D-C37E607EA019</gtr:id><gtr:title>Biosynthesis of mycobacterial arabinogalactan: identification of a novel alpha(1--&amp;gt;3) arabinofuranosyltransferase.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cc553143c062c43864af4ca99cc7410"><gtr:id>2cc553143c062c43864af4ca99cc7410</gtr:id><gtr:otherNames>Birch HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>9E20CCCD39F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F376E82A-ECC4-4CD1-8E87-B71EAEFBB97C</gtr:id><gtr:title>Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91de3dc0304a58e0b9621946f2c755ee"><gtr:id>91de3dc0304a58e0b9621946f2c755ee</gtr:id><gtr:otherNames>Gobec S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>C1BF8F251A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEC1DF03-01DF-4672-8852-86E48EA927C8</gtr:id><gtr:title>Mycobacterium marinum MMAR_2380, a predicted transmembrane acyltransferase, is essential for the presence of the mannose cap on lipoarabinomannan.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cb7f3376d16bd3006f3cd723558baf6"><gtr:id>7cb7f3376d16bd3006f3cd723558baf6</gtr:id><gtr:otherNames>Driessen NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn><gtr:outcomeId>X5RGmnfrm1u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8639BCA-995A-4AD1-9969-B2F1FAA824F3</gtr:id><gtr:title>Identification of a novel arabinofuranosyltransferase AftB involved in a terminal step of cell wall arabinan biosynthesis in Corynebacterianeae, such as Corynebacterium glutamicum and Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/220f3e1279de29ab5137020a78c0475f"><gtr:id>220f3e1279de29ab5137020a78c0475f</gtr:id><gtr:otherNames>Seidel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CD95A57B1CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15BD09C4-9D9B-498B-98DB-191C4E8EFFE9</gtr:id><gtr:title>Topology and mutational analysis of the single Emb arabinofuranosyltransferase of Corynebacterium glutamicum as a model of Emb proteins of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/220f3e1279de29ab5137020a78c0475f"><gtr:id>220f3e1279de29ab5137020a78c0475f</gtr:id><gtr:otherNames>Seidel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>7E8CD4D9E46</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4221535B-1192-4204-9406-2DED3B505112</gtr:id><gtr:title>Inactivation of Mycobacterium tuberculosis mannosyltransferase pimB reduces the cell wall lipoarabinomannan and lipomannan content and increases the rate of bacterial-induced human macrophage cell death.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a033ea3739834996f6793c23550b164b"><gtr:id>a033ea3739834996f6793c23550b164b</gtr:id><gtr:otherNames>Torrelles JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>92CA341DB0E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>177A9F51-681D-4FF1-A79E-0D42014ECCA4</gtr:id><gtr:title>Dimerization of inositol monophosphatase Mycobacterium tuberculosis SuhB is not constitutive, but induced by binding of the activator Mg2+.</gtr:title><gtr:parentPublicationTitle>BMC structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/962767f96f457e07606b64e91d28b5fd"><gtr:id>962767f96f457e07606b64e91d28b5fd</gtr:id><gtr:otherNames>Brown AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1472-6807</gtr:issn><gtr:outcomeId>76BFBA3E936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D019955-3038-4BBB-99E7-F4F15B95E936</gtr:id><gtr:title>Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b2c58e57e9ab1ad2c24e9a9f0d3183"><gtr:id>a1b2c58e57e9ab1ad2c24e9a9f0d3183</gtr:id><gtr:otherNames>Kalscheuer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>d2Bcm1aYFpF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>888593F1-FEF5-4B5F-A3CD-A34B8E42F995</gtr:id><gtr:title>Lipoarabinomannan biosynthesis in Corynebacterineae: the interplay of two a(1?2)-mannopyranosyltransferases MptC and MptD in mannan branching.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1764466a9db2af8c2be90c94ee57fb4e"><gtr:id>1764466a9db2af8c2be90c94ee57fb4e</gtr:id><gtr:otherNames>Mishra AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>NkvVZwn9BRS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A96F4D43-F33E-4BA1-810E-5BBA2324C6F9</gtr:id><gtr:title>Identification of a glycosyltransferase from Mycobacterium marinum involved in addition of a caryophyllose moiety in lipooligosaccharides.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0efde154948da31d981e80f575a9d27f"><gtr:id>0efde154948da31d981e80f575a9d27f</gtr:id><gtr:otherNames>Sarkar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>BetkZmppawc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC8D074D-E331-48DC-B0C5-40A256779AAF</gtr:id><gtr:title>Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74aaa8e47112a3ae798b15a63c7ab34e"><gtr:id>74aaa8e47112a3ae798b15a63c7ab34e</gtr:id><gtr:otherNames>Guillonneau C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>6FBA82E87A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9D7996C-906D-4AD2-96A6-BA698EE69B10</gtr:id><gtr:title>Structural characterization of a partially arabinosylated lipoarabinomannan variant isolated from a Corynebacterium glutamicum ubiA mutant.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a10ca0f4eb0dcb93009bf9ad8cb79c29"><gtr:id>a10ca0f4eb0dcb93009bf9ad8cb79c29</gtr:id><gtr:otherNames>Tatituri RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn><gtr:outcomeId>E49777B4E2C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500590</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>